Menu
Currency
GWAS Study

High incidence and geographic distribution of cleft palate in Finland are associated with the IRF6 gene.

Rahimov F, Nieminen P, Kumari P et al.

39500877 PubMed ID
GWAS Study Type
708171 Participants
76 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

RF
Rahimov F
NP
Nieminen P
KP
Kumari P
JE
Juuri E
NT
Nikopensius T
PK
Paraiso K
GJ
German J
KA
Karvanen A
KM
Kals M
EA
Elnahas AG
KJ
Karjalainen J
KM
Kurki M
PA
Palotie A
HA
Heliövaara A
ET
Esko T
JS
Jukarainen S
PP
Palta P
GA
Ganna A
PA
Patni AP
MD
Mar D
BK
Bomsztyk K
MJ
Mathieu J
RH
Ruohola-Baker H
VA
Visel A
FW
Fakhouri WD
SB
Schutte BC
CR
Cornell RA
RD
Rice DP
Chapter II

Abstract

Summary of the research findings

In Finland, the frequency of isolated cleft palate (CP) is higher than that of isolated cleft lip with or without cleft palate (CL/P). This trend contrasts to that in other European countries but its genetic underpinnings are unknown. We conducted a genome-wide association study in the Finnish population and identified rs570516915, a single nucleotide polymorphism highly enriched in Finns, as strongly associated with CP (P = 5.25 × 10-34, OR = 8.65, 95% CI 6.11-12.25), but not with CL/P (P = 7.2 × 10-5), with genome-wide significance. The risk allele frequency of rs570516915 parallels the regional variation of CP prevalence in Finland, and the association was replicated in independent cohorts of CP cases from Finland (P = 8.82 × 10-28) and Estonia (P = 1.25 × 10-5). The risk allele of rs570516915 alters a conserved binding site for the transcription factor IRF6 within an enhancer (MCS-9.7) upstream of the IRF6 gene and diminishes the enhancer activity. Oral epithelial cells derived from CRISPR-Cas9 edited induced pluripotent stem cells demonstrate that the CP-associated allele of rs570516915 concomitantly decreases the binding of IRF6 and the expression level of IRF6, suggesting impaired IRF6 autoregulation as a molecular mechanism underlying the risk for CP.

228 Finnish (founder/genetic isolate) cases, 308,799 Finnish (founder/genetic isolate) controls

Chapter III

Study Statistics

Key metrics and study information

708171
Total Participants
GWAS
Study Type
Yes
Replicated
165 Finnish (founder/genetic isolate) cases, 199,935 Finnish (founder/genetic isolate) controls, 71 Estonian (founder/genetic isolate) cases, 198,973 Estonian (founder/genetic isolate) controls
Replication Participants
European
Ancestry
Finland, Estonia
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.